Evaxion announces business update and full year 2023 financial results

Copenhagen, denmark, march 27, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today provides a business update and announces full year 2023 financial results.
EVAX Ratings Summary
EVAX Quant Ranking